NRG
EDIT icon

Nemes Rush Group’s Editas Medicine EDIT Stock Holding History

Nemes Rush Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50
Closed -$124 – 960
2026
Q1 		$124 Hold
50
– – ﹤0.01% 927
2025
Q4 		$103 Hold
50
– – ﹤0.01% 970
2025
Q3 		$174 Hold
50
– – ﹤0.01% 670
2025
Q2 		$110 Hold
50
– – ﹤0.01% 709
2025
Q1 		$58 Hold
50
– – ﹤0.01% 699
2024
Q4 		$64 Hold
50
– – ﹤0.01% 718
2024
Q3 		$371 Hold
50
– – ﹤0.01% 577
2024
Q2 		$234 Hold
50
– – ﹤0.01% 589
2024
Q1 		$371 Hold
50
– – ﹤0.01% 637
2023
Q4 		$507 Hold
50
– – ﹤0.01% 624
2023
Q3 		$390 Hold
50
– – ﹤0.01% 619
2023
Q2 		$412 Buy
+50
New +$436 ﹤0.01% 645

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Nemes Rush Group's EDIT Position: Q2 2026 in Review

Nemes Rush Group sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 50 shares — an estimated $124 sold.

Nemes Rush Group first reported a position in EDIT in Q2 2023 and held it in 12 quarters. The position peaked at $507 in Q4 2023. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Nemes Rush Group reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • Nemes Rush Group sold 50 Editas Medicine shares in Q2 2026, an estimated $124.
  • Nemes Rush Group first reported a position in Editas Medicine in Q2 2023 and held it in 12 quarters.
  • Nemes Rush Group's Editas Medicine position peaked at $507 in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.